GE HealthCare Raises Quarterly Dividend 14.3% to $0.04

GE HealthCare Technologies Inc. raised its quarterly dividend 14.3% to $0.04 a share from $0.035. The shares traded ex-dividend on October 23, 2026, and the payment is due November 13, 2026.

Why the dividend changed

The board’s dividend declaration did not provide a specific reason for the increase. The company’s recent financial performance and capital-allocation plans provide the relevant context: GE HealthCare is generating earnings and cash while balancing shareholder distributions, investment, share repurchases and acquisitions.

In its second-quarter results, GE HealthCare reported revenue growth of 5.7%, organic orders growth of 11.1% and a backlog of $23.9 billion. Free cash flow was $68 million for the quarter and $180 million for the first half. The company reaffirmed full-year free-cash-flow guidance of approximately $1.6 billion. CEO Peter Arduini said record orders and backlog reflected commercial execution and adoption of new products.

Performance was uneven. Advanced Imaging Solutions and Pharmaceutical Diagnostics expanded, while Patient Care Solutions remained challenged. Management said it was reviewing strategic options for Patient Care Solutions to maximize the business’s long-term value. Inflation associated with memory chips, oil, freight and other components also remained part of the full-year outlook.

The higher dividend is consistent with GE HealthCare’s stated approach to capital allocation. Its capital-allocation presentation lists quarterly dividends and opportunistic share repurchases alongside organic investment, acquisitions and maintenance of an investment-grade balance sheet. In the second quarter, the company repurchased $200 million of stock and reported $500 million remaining under its authorization. This context helps explain the board’s capacity to lift the payment, although management did not identify any one factor as the cause.

Dividend track record

GE HealthCare’s dividend history is short but has moved upward. The company distributed $0.09 through 3 payments in 2023. The annual total rose 33.3% to $0.12 in 2024 and increased another 16.7% to $0.14 in 2025.

Payments remained at $0.035 from January 14, 2025, through July 24, 2026, before increasing to $0.04 for the October 23, 2026, ex-dividend date. The latest action gives GE HealthCare 1 consecutive year of dividend growth. The stated annualized dividend is now $0.16 a share, or $16.00 of annual income per 100 shares. The record shows a gradually rising distribution rather than an established long-duration growth streak.

Is the dividend covered?

The dividend consumes 3% of earnings. That low payout ratio indicates a wide earnings cushion: most profit remains inside the company for debt service, investment, acquisitions, repurchases and other corporate needs after the dividend is paid.

SmarterDividends rates the dividend B, with a safety score of 73. That places it in the safe (66-79) range. In plain terms, current earnings coverage supports the payment, while the grade stops short of the highest tier because dividend safety also depends on operating consistency, cash generation, leverage and competing capital demands.

Those competing demands are visible. GE HealthCare ended the second quarter with $10.1 billion of debt outstanding and continued to invest in capacity and innovation. The small earnings payout limits the dividend’s claim on corporate resources as management pursues those priorities.

Yield and valuation

At a share price of $71.45, GE HealthCare’s forward yield is 0.22%. That is well below the Healthcare sector median forward yield of 1.67%. The increase improves the cash payment, but GEHC remains a low-yielding healthcare stock. Its shares have recorded a 10.7% loss over one year.

SmarterDividends estimates fair value at $90.86 and classifies the shares as undervalued, representing 27% upside to that estimate. The fair-value gap is a valuation assessment rather than a forecast. GE HealthCare’s market value is $32.5 billion.

What to watch

The next confirmed dividend milestone is the November 13, 2026, payment. The next operating update follows sooner: GE HealthCare has scheduled its third-quarter results for October 28, 2026. Investors will receive updated information on orders, backlog, Patient Care Solutions, cash generation and whether management changes its full-year guidance.

Capital deployment is another concrete issue. GE HealthCare agreed to acquire SOFIE Biosciences for $945 million in cash, subject to regulatory approvals and other closing conditions. The transaction is expected to close in the first half of 2027 and would expand the Pharmaceutical Diagnostics segment’s U.S. PET radiopharmaceutical manufacturing and distribution footprint. Progress toward closing, funding of the purchase and management’s strategic review of Patient Care Solutions will frame the company’s capital-allocation discussion alongside the higher dividend.